Bentzien, F., Zuzow, M., Heald, N., Gibson, A., Shi, Y., Goon, L., . . . Yakes, F. M. (2013). In Vitro and In Vivo Activity of Cabozantinib (XL184), an Inhibitor of RET, MET, and VEGFR2, in a Model of Medullary Thyroid Cancer. Mary Ann Liebert, Inc.
Citação norma ChicagoBentzien, Frauke, et al. In Vitro and In Vivo Activity of Cabozantinib (XL184), an Inhibitor of RET, MET, and VEGFR2, in a Model of Medullary Thyroid Cancer. Mary Ann Liebert, Inc, 2013.
Citação norma MLABentzien, Frauke, et al. In Vitro and In Vivo Activity of Cabozantinib (XL184), an Inhibitor of RET, MET, and VEGFR2, in a Model of Medullary Thyroid Cancer. Mary Ann Liebert, Inc, 2013.
Nota: a formatação da citação pode não corresponder 100% ao definido pela respectiva norma.